BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berglund MM, Strömberg P. The clinical potential of Affibody-based inhibitors of C5 for therapeutic complement disruption. Expert Review of Proteomics 2016;13:241-3. [DOI: 10.1586/14789450.2016.1148604] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Frejd FY, Kim KT. Affibody molecules as engineered protein drugs. Exp Mol Med 2017;49:e306. [PMID: 28336959 DOI: 10.1038/emm.2017.35] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 17.6] [Reference Citation Analysis]
2 Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren PÅ, Löfblom J. Affibody Molecules in Biotechnological and Medical Applications. Trends Biotechnol 2017;35:691-712. [PMID: 28514998 DOI: 10.1016/j.tibtech.2017.04.007] [Cited by in Crossref: 122] [Cited by in F6Publishing: 118] [Article Influence: 24.4] [Reference Citation Analysis]
3 Barozzi A, Lavoie RA, Day KN, Prodromou R, Menegatti S. Affibody-Binding Ligands. Int J Mol Sci 2020;21:E3769. [PMID: 32471034 DOI: 10.3390/ijms21113769] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Chu W, Prodromou R, Day KN, Schneible JD, Bacon KB, Bowen JD, Kilgore RE, Catella CM, Moore BD, Mabe MD, Alashoor K, Xu Y, Xiao Y, Menegatti S. Peptides and pseudopeptide ligands: a powerful toolbox for the affinity purification of current and next-generation biotherapeutics. J Chromatogr A 2021;1635:461632. [PMID: 33333349 DOI: 10.1016/j.chroma.2020.461632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mazigi O, Schofield P, Langley DB, Christ D. Protein A superantigen: structure, engineering and molecular basis of antibody recognition. Protein Eng Des Sel 2019;32:359-66. [PMID: 31641749 DOI: 10.1093/protein/gzz026] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol 2018;14:26-47. [PMID: 29199277 DOI: 10.1038/nrneph.2017.156] [Cited by in Crossref: 196] [Cited by in F6Publishing: 183] [Article Influence: 39.2] [Reference Citation Analysis]
7 Verdino P, Atwell S, Demarest SJ. Emerging trends in bispecific antibody and scaffold protein therapeutics. Current Opinion in Chemical Engineering 2018;19:107-23. [DOI: 10.1016/j.coche.2018.01.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]